Year All202420232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998 BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update Aug 05, 2024 Read More BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Aug 02, 2024 Read More BioCryst to Report Second Quarter 2024 Financial Results on August 5 Jul 22, 2024 Read More ORLADEYO® (berotralstat) Approved in Peru Jul 09, 2024 Read More BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jul 02, 2024 Read More BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jun 04, 2024 Read More BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) Treatment Jun 02, 2024 Read More BioCryst to Present New Data at 2024 Meeting of the European Academy of Allergy and Clinical Immunology May 14, 2024 Read More ORLADEYO® (berotralstat) Approved in Mexico May 13, 2024 Read More BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO® (berotralstat) May 09, 2024 Read More
BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update Aug 05, 2024 Read More
BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) Treatment Jun 02, 2024 Read More
BioCryst to Present New Data at 2024 Meeting of the European Academy of Allergy and Clinical Immunology May 14, 2024 Read More
BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO® (berotralstat) May 09, 2024 Read More